Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05806762

Prediction of Rehospitalization Following a Sepsis Admission Using a Wearable Biopatch

The goal of this observational study is to learn about the utility of biopatches predicting 30-day readmissions in patients discharged from the hospital with sepsis.

The main question[s] it aims to answer are:

• Does the application of a biopatch provide data that can improve prediction of an unplanned 30-day readmission following a hospitalization for sepsis.

Participants will be asked to wear a biopatch on their chest for 30-days following hospital discharge or until readmission to the hospital.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

UC San Diego Health

San Diego, California, 92103, United States

Location status: Recruiting

Location contact

Gabriel Wardi

CONTACT

[email protected]

619-543-6463

About this study

Study Design: Longitudinal cohort study with repeated measure of outcomes and predictors.

The BioIntelliSense patch is an FDA approved wearable device that is applied to the chest with a 30-day battery lifespan and allows for real-time monitoring of heart rate, respiratory rate, skin temperature, general activity, severe cough episodes, and sedentary body position, among others.

Outcomes of Interest: Hospital readmission within 30 days of discharge following an index admission with a diagnosis of sepsis is the primary outcome of interest for this study. We will calculate the positive predictive value (PPV) of readmission prediction as the the primary outcome of interest from the following approaches: analytic score plus biopatch, analytic score alone, LACE+ score. Secondary outcomes include area under the curve of the receiver operator characteristic (AUCroc) of predictive scores (analytic score and biopatch, analytic score alone, LACE+ score) and number of patients readmitted to the hospital within 30 days of discharge.

Protocol for Patient Selection and Application of Biopatch: Patients who meet "Sepsis 3" definition will be identified with institutional review board (IRB)-approved screening protocols. Our previously derived and validated machine-learning algorithm to predict unplanned 30-day readmissions will then generate daily predictions about 30-day readmission probability which will be recorded, as well as LACE+ scores. As a patient approaches discharge, the treatment team and patient (or legally authorized representative) will be approached about potential enrollment. If there is agreement to enroll in this prospective study, then we will apply the patch at the time of discharge. Patients will then be followed with the BioIntellisence patch with augmented and real-time risk predictions based on data obtained from this. For this proposal, we will use data from the BioIntelliSense patch and are not providing clinicians with data on risk of readmission.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Age >= 18 years Development of sepsis, defined by recent international guidelines (Suspected infection AND 2-point change in sequential organ failure assessment (SOFA) score), in emergency department or hospital Admission to hospital from emergency department

Exclusion criteria

Transition to comfort measures within 6 hours of time of sepsis Discharge from the emergency department Admission to bone marrow transplant service Severe burn or other dermatologic condition that will prevent application to skin

Treatment and study plan

BioIntellisense

Device

Enrolled patients will have a Fitbit placed on their wrist. There is no comparator group enrolled.

Primary outcomes

  1. Hospital readmission

    Time frame: 30 days

    Patients with an index hospitalization with sepsis will be followed to see if they have an unplanned readmission to the hospital.

Secondary outcomes

  1. Area under the curve of the receiver operating characteristic

    Time frame: 30 days

    AUCroc of predictive scores (analytic score and biopatch, analytic score alone, LACE+ score)

  2. Positive predictive value

    Time frame: 30 days

    PPV of of predictive scores (analytic score and biopatch, analytic score alone, LACE+ score)

Study contacts

Contact information is provided by the study sponsor or research team.

Gabriel Wardi

CONTACT

[email protected]

6195436463

Shamim Nemati

CONTACT

Sponsors and collaborators

Lead sponsor

University of California, San Diego

Other

Registry information

Official study title

Prediction of Rehospitalization Following a Sepsis Admission Using a Wearable Biopatch and Deep Learning Model

Important dates

Study start
2023
Primary completion
2027
Study completion
2027
First posted
Apr 10, 2023
Registry last updated
Apr 3, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.